Gene · 6146
RPL22: ribosomal protein L22
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL22: ribosomal protein L22. Genes, record 6146. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6146
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P35268 | Large ribosomal subunit protein eL22 | 128 | 142 | Ensembl, GeneID, HGNC |
Source UniProt
Patents44
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 62005 | P35268 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 7031 | P35268 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 6912 | P35268 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5215 | P35268 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 6912 | P35268 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 7031 | P35268 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5215 | P35268 | Espacenet |
| US 11884978 B2 | 2024-01-30 | 717 | P35268 | Espacenet |
| JP 2024009871 A | 2024-01-23 | 77 | P35268 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74003 | P35268 | Espacenet |
1 to 10 of 44
See all 44 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants1,144
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL22 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 6 | 2025 |
| P30DK050306 | Center for Molecular Studies in Digestive and Liver Diseases | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 4 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 4 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 4 | 2025 |
| ZIAHG200338 | Molecular Analyses of Endometrial Cancer | 4 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 3 | 2025 |
| P30CA072720 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,144Source NIH's project files
See all 1,144 nih grantsPapers1,572
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Translational control by RPL22L1-specific ribosomes enhances DNA repair and chemoresistance. | Nat Commun | 2026 | 42680749 | PubTator, text mining | PubMed |
| Endothelial DANCR deficiency promotes atherosclerotic plaque instability by targeting ribosomal protein L22. | J Adv Res | 2026 | 42668039 | PubTator, text mining | PubMed |
| BAG6-RNF115 Couples Protein Quality Control with Ribosome Assembly. | bioRxiv | 2026 | 42620044 | PubTator, text mining | PubMed |
| Phylogenomic discordance among plastid genes in endangered Maltese Limonium. | Sci Rep | 2026 | 42288520 | PubTator, text mining | PubMed |
| A RiboCancer cell line panel reveals that CLL-associated Rps15 mutations translationally rewire transcription through codon-specific tRNA accommodation defects. | Hemasphere | 2026 | 42255948 | PubTator, text mining | PubMed |
| Loss of ribosomal protein RPL22 restricts African swine fever virus replication by inducing PERK-dependent ER stress. | Emerg Microbes Infect | 2026 | 42175753 | PubTator, text mining | PubMed |
| Anatomy and the chloroplast genome of Bischofia plants reveal important phylogenetic relationship and the genetic diversity in phyllanthaceae. | Sci Rep | 2026 | 42128939 | PubTator, text mining | PubMed |
| Targeting tRNA-dependent tyrosine usage unveils a metabolic vulnerability in hepatocellular carcinoma. | Nat Commun | 2026 | 41792125 | PubTator, text mining | PubMed |
| Nucleolus as a cornerstone linking proliferation and metabolism to cellular responses to stress: involvement of transcription factors MYC and p53. | Front Mol Biosci | 2026 | 41777667 | PubTator, text mining | PubMed |
| Integrative Spatial Transcriptomics and Immunoinformatics for Prognostic Multi-Epitope Vaccine Construct Prediction Against Synovial Sarcoma. | Pharmaceuticals (Basel) | 2026 | 41754822 | PubTator, text mining | PubMed |
1 to 10 of 1,572
See all 1,572 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6146
GET https://conductscience.org/api/genes/v1/6146/patents?page=2